Melanie Kripp

Summary

Affiliation: University of Heidelberg
Country: Germany

Publications

  1. ncbi Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine
    Melanie Kripp
    Onkologisches Zentrum, III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität, Heidelberg, Germany
    Int J Nanomedicine 3:397-401. 2008
  2. ncbi Alpha-fetoprotein expressing metastastic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin
    Melanie Kripp
    Onkologisches Zentrum, III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Anticancer Drugs 20:75-8. 2009
  3. ncbi Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status
    Nadine Lukan
    III Medizinische Klinik, Universitatsmedizin Mannheim, Mannheim, Deutschland
    Oncology 77:293-9. 2009
  4. ncbi Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma
    Jens Kruth
    III Medizinische Klinik, Hämatologie und Onkologie, Universitatsmedizin Mannheim, Ruprecht Karls Universitat Heidelberg, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    J Cancer Res Clin Oncol 136:1845-51. 2010
  5. ncbi Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer--an extended phase I MARGIT and AIO trial
    Ralf Dieter Hofheinz
    Onkologisches Zentrum, III Medizinische Klinik Mannheim, Medizinische Fakultät Mannheim der Universität Heidelberg, Heidelberg, Germany
    Int J Radiat Oncol Biol Phys 73:142-7. 2009

Collaborators

Detail Information

Publications5

  1. ncbi Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine
    Melanie Kripp
    Onkologisches Zentrum, III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität, Heidelberg, Germany
    Int J Nanomedicine 3:397-401. 2008
    ..In this review we briefly summarize the clinical data and discuss them in light of clinical problems and possible treatment scenarios...
  2. ncbi Alpha-fetoprotein expressing metastastic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin
    Melanie Kripp
    Onkologisches Zentrum, III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Anticancer Drugs 20:75-8. 2009
    ..He was treated with capecitabine and oxaliplatin-based combination therapy. A long-lasting major remission was observed resulting in a survival of 18.5 months...
  3. ncbi Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status
    Nadine Lukan
    III Medizinische Klinik, Universitatsmedizin Mannheim, Mannheim, Deutschland
    Oncology 77:293-9. 2009
    ..Anal cancers universally express the epidermal growth factor receptor (EGFR) and KRAS mutations have not been reported in anal cancer thus far...
  4. ncbi Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma
    Jens Kruth
    III Medizinische Klinik, Hämatologie und Onkologie, Universitatsmedizin Mannheim, Ruprecht Karls Universitat Heidelberg, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    J Cancer Res Clin Oncol 136:1845-51. 2010
    ..Therefore, we have established a combination regimen of these drugs (DocMitoCape), which demonstrated preliminary activity especially in bile duct and pancreatic carcinoma...
  5. ncbi Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer--an extended phase I MARGIT and AIO trial
    Ralf Dieter Hofheinz
    Onkologisches Zentrum, III Medizinische Klinik Mannheim, Medizinische Fakultät Mannheim der Universität Heidelberg, Heidelberg, Germany
    Int J Radiat Oncol Biol Phys 73:142-7. 2009
    ..We sought to determine the maximum tolerated dose and the dose-limiting toxicities (DLT) of these drugs in combination with intensity-modulated radiotherapy...